Here are the most recent posters presented in international meetings. You can achieve them applying to info@forenap.com.
2010ESRS 2010 (Lisbon, Portugal), September 14-18, 2010
- Cornette F, Pross N, Trecherel C, Gardinier S, Mallet de Chauny E, Metzger D, Guinot C, Muzet A, Morizot F, Staner L. Mood and REM sleep effects of a 6-day 4-h sleep restriction protocol in healthy female subjects
- Staner L, Cornette F, Pross N, Trecherel C, Girard N, Mallet de Chauny E, Metzger D, Muzet A. Differential sleep EEG effects of sleep restriction versus temazepam in healthy subjects and patients with psychophysiological insomnia.
23rd ECNP (Amsterdam, The Netherlands) August 28 – September 1, 2010
- Parks V, Patat A, Plotka A, Raje S, Wesnes K, Boeijinga P. Comparison of AChE inhibition and 5-HT1A blockade in healthy young volunteers on a scopolamine-challenge model of cognitive impairment.
NCDEU 2010 (Boca Raton, Florida), June 14-17, 2010
- Luthringer R, Ferguson J, Boeijinga P, Pross N, Staner C. Soufflet L, Maurice D, Viardot G, Danjou P. Assessment of spontaneous and evoked gamma oscillations by quantified EEG, a potential biomarker of glutamatergic transmission : methodological issues in humans, descriptive data and test-retest reliability.
APSS 2010 (San Antonio, Texas, USA), June 5-9, 2010
- Greenblatt DJ, Danjou P, Luthringer R, Metzger D, Otmani S, Pross N, Osbakken M, McCormick A, Walsh J. Phase I, randomized, double-blind, placebo-controlled, crossover study to compare the pharmacokinetics of a single oral dose of a new zaleplon formulation (SKP-1041) and open label zaleplon in healthy elderly subjects.
- Staner L, Luthringer R, Viardot G, Metzger D, Tisserant A, Osbakken M, McCormick A, Walsh JK, Greenblatt DJ. Phase I, randomized, crossover study to compare day vs night pharmacokinetics of a single oral dose of a new zaleplon forumulation in healthy young volunteers.
ASCPT 2010 (Atlanta, USA), March 17-20, 2010
- Luthringer R, Muzet M, Boeijinga P. An electroencephalographic study with brain oscillatory recording to assess how benzodiazepines affect auditory versus visual cognitive processes.
- Cornette F, Metzger D, Muzet A, Luthringer R, Staner L. Comparison of the post-nap versus first-night effect models of transient insomnia by means of visual and spectral sleep EEG analyses.
14th IHS - International Headache Congress (Philadelphia, USA), September 10-13, 2009
- Djupesland PG, Luthringer R, Docekal P. Can Nose-to-Brain transport of anti-migraine drugs along the trigeminal nerve improve therapeutic effects while minimizing the risk of systemic adverse events?
17th European Signal Processing Conference (Glasgow, UK), August 24-28, 2009
- Tohmé M, Lengellé R. Sequential maximum gradient optimization for support vector detection.
APSS (Seatle, USA), June 6-11, 2009
- Otmani S, Soufflet L, Staner L, Luthringer R. Pharmacodynamic profile of three novel formulations of Zaleplon versus placebo and marketed Zaleplon measured by electroencephalography in healthy volunteers.
- Walsh J, Cornette F, Staner C, Tisserant A, Luthringer R, Staner L. Pharmacodynamic profile of three novel formulations of Zaleplon in normal volunteers as evaluated by the Multiple Sleep Latency Test.
- Gassen M, Kress A, Nedelec J, Francart C, Staner C. Pharmacokinetic profile of single oral doses of Zaleplon in three novel formulations in normal volunteers.
- Pross N, Staner L, Luthringer R, Staner C. Use of the addiction research center inventory (sedation subscale) and the Karolinska Sleepiness Scale to evaluate subjective alertness after single oral doses of Zaleplon in three novel formulations.
- Luthringer R, Pross N, Otmani S, Staner C, Staner L. Relationship of subjective and objective endpoints for outcomes of a phase I trial of a potential new sleep agent.
- Vanover K, Staner L, Luthringer R, Mates S, Davis R. ITI-007 / ITI-722, A new Approach for the treatment of sleep maintenance insomnia and sleep disorders associated with psychiatric and neurological diseases.
- Luthringer R, Floch A, Delfolie A, Nicolas O, Brunet A, Pinquier J (presented by Staner L). Effects of Eplivanserin, a non-sedative agent, on driving an cognitive/psychomotor performance a randomizes placebo-and active-controlled trial in insomnia patients with difficulties maintaining sleep.
MMN’09 (Budapest, Hungary) April 4-7, 2009
15th IPEG meeting (Rouffach, France), September 24-27th, 2008
- Boeijinga PH, Soufflet L, Luthringer R. P300 differences in averaged event related potentials and event related oscillations: ketamine, apomorphine and the model for an endophenotype for schizophrenia.
- Tohme M, Lengellé R, Boeijinga PH. Classification of psychotropic drugs: validation of neurophysiological markers projected in a high dimensional space.
ESRS 2008 (Glasgow, UK), September 9-13, 2008
- Berthomier C, Muzet A, Berthomier P, Prado J, Mattout J. Real-Time Automatic Measure of Drowsiness based on a Single EEG Channel.
APSS - Sleep 2008 (Baltimore, USA), June 7-12, 2008
- Birznieks G, Feeney, J, Liv S, Baroldi P, Luthringer R, Staner L, Martzloff D, Polymeropoulos M. Clinical study of VSF-173 in a model of excessive sleepiness. Abstracted in Sleep 2008;31(abstract suppl):A129.
AAN 2008 (Chicago, USA), April 12-19, 2008
- Luthringer R, Sheldrake CD, Flint A, Djupesland PG. Intranasal Sumatriptan Powder Delivered with a New Device is as Effective as 6 mg SC Sumatriptan in Preventing Glyceryltrinitrate (GTN) Challenge Induced EEG Changes in Migraineurs.
ICASSP 08 (Las Vegas, USA), March 30-April 5, 2008
- Tohme M, Lengellé R. F-SVR: a new learning algorythm for support vector regression.
2nd WEBP Meeting (West European Societies of Biological Psychiatry) (Strasbourg, France), December 13-15, 2007
- Boeijinga PH, Soufflet L, Luthringer R. P300 differences in averaged Event Related Potentials and Event Related Oscillations : ketamine, apomorphine and the model for an endophenotype for schizophrenia.
- Foucher J, Vidailhet P, Boeijinga PH, Hodé Y, Soufflet L , Pham BT, Danion JM. Abnormal functional integration in schizophrenia: fMRI and MEG imaging are pointing to the same issues. Abstracted in Eur Arch Psychiatry Clin Neurosci 2007 ; 257 (suppl 2): 31-32. [Best Poster Award]
46th Annual ACNP Meeting (Boca-Raton, Florida, USA), December 9-13, 2007
- Luthringer R, Boeijinga PH, Muzet M, Ferguson J. Comparison of the effects of benzodiazepines on induced gamma activity in auditory and visual cognitive tasks.
Neurex BCCN Meeting 2007 (Freiburg-im-Breisgau, Germany) June 22-23, 2007
- Boeijinga P. Synchronization distinguishes drug effects on cognitive responses in visual modality from auditory ‘oddball’: human neuropharmacology of GABAergic transmission.
47th Annual NCDEU Meeting (Boca Raton, USA), June 11-14, 2007
- Boeijinga P, Dunbar G, Demazières A (presented by R. Luthringer). Brain nicotinic stimulation in healthy volunteers causes EEG changes which precede improvement in attention and episodic memory.
Annual Meeting of ISMRM and ESMRMB (International and European Societies for Magnetic Resonance in Medicine) (Berlin, Germany), May 19-25, 2007
- Mathis A. Attention inhibitory process decline during life span: a functional MRI study.
2007 International Congress on Schizophrenia Research (Dallas, USA), March 28- April 12, 2007
- Luthringer R, Staner L, Noel N, Muzet M, Gassmann-Mayer C, Talluri K, Cleton A, Palumbo J, Eerdekens M. Sleep assessments in patients with schizophrenia following treatment with paliperidone extended-release tablets.
19h Annual US Psychiatric & mental Health Congress (New Orleans, USA), November 16-19th, 2006
- Luthringer R, Staner L, Noel N, Muzet M, Gassmann-Mayer C, Talluri K, Cleton A, Palumbo J, Eerdekens M. Sleep assessments in patients with schizophrenia following treatment with paliperidone extended-release tablets.
58h Institute on Psychiatric Services (New York, USA), October 5-8th, 2006
- Luthringer R, Staner L, Noel N, Muzet M, Gassmann-Mayer C, Talluri K, Cleton A, Palumbo J, Eerdekens M. Sleep assessments in patients with schizophrenia following treatment with paliperidone extended-release tablets.
19th ECNP Congress (Paris, France), September 16-20th, 2006
- Luthringer R, Staner L, M. Noel, Muzet M, Gassmann-Mayer C, Talluri K, Cleton A, Eerdekens M, Palumbo J. Sleep assessments in patients with schizophrenia following treatment with paliperidone extended-release tablets.
ESRS 2006 : 18th ESRS Congress (Innsbruck, Austria), September 12-16th, 2006
- Cornette F, D Metzger, F Calvi-Gries, K Bouylout, Muzet A, Luthringer R, Staner L. Post-nap or First Night effect as model for transient insomnia: a comparison of visual and spectral analysis of sleep EEG. Abstracted in J Sleep Res 15(suppl.1);156:2006.
- Lundahl J, Staner L, Deacon S. Differences between spectral profiles during NREM sleep for gaboxadol and zolpidem in the short-term treatment of patients with primary insomnia. Abstracted in J Sleep Res 15(suppl.1);195:2006.
- Lundahl J, Staner L, Staner C, Deacon S. The selective extrasynaptic GABAa agonist gaboxadol improves sleep maintenance and enhances slow wave sleep in adult patients with primary insomnia. Abstracted in J Sleep Res 15(suppl.1);194-195:2006.
13th World Congress of Psychophysiology (Istanbul, Turquie) August 28th- September 2nd, 2006
- Mathis A. Attention inhibitory process decline during life span: a fMRI study.
20th Annual Meeting of APSS (Salk Lake City, USA), June 17-22nd, 2006
- Douglass A, Ward M, Viardot G, Staner L. Markov analysis of eye movement density in normal controls under tryptophan depletion and acute fluvoxamine treatment. Abstracted in Sleep 2006 ; 29 :A3331-2.
- Lundahl J, Staner L, Deacon S. Spectral profiles during NREM sleep for gaboxadol and zolpidem in the treatment of patients with primary insomnia. Abstracted in Sleep 2006 ;29:A244.
- Lundahl J, Staner L, Staner C, Deacon S. Gaboxadol improves sleep maintenance and, in contrast to zolpidem, enhances slow wave sleep in adult patients with primary insomnia. Abstracted in Sleep 2006. 29;A244.
- Luthringer R, Prosser W, Arnal MA, Martin M, Staner C, Shanahan W, Staner L. Pharmacokinetic and pharmacodynamic effects of the selective 5-HT2a inverse agonist APD125 in healthy adults. Abstracted in Sleep 29;A39:2006.
- Staner L, Muscat N, Cornette F, Santoro F, Pettersson A, Roth T, Luthringer R. Sublingual zolpidem compared to oral zolpidem in the post-nap sleep model of insomnia. Abstracted in Sleep 2006 ;29:A254.
46th Annual NCDEU Meeting (Boca Raton, USA), June 12-15th, 2006
- Luthringer R, Noel N, Muzet M, Gassmann-Mayer C, Talluri K, Cleton A, Eerdekens M, Palumbo J, Staner L. Sleep assessments in patients with schizophrenia following treatment with paliperidone extended-release tablets.
12th Annual Meeting Human Brain Mapping (Florence, Italy), June 11-15th, 2006.
- Schunck T, Erb G, Mathis A, Gilles C, Namer IJ, Hode Y, Demaziere A, Luthringer R, Macher JP. Functional Magnetic Resonance Imaging characterization of CCK-4-induced panic attack.
- Schunck T, Erb G, Jacob N, Mathis A, Gilles C, Namer IJ, Luthringer R. Experimentally induced anxiety in healthy volunteers: clinical, autonomic and brain functional response.
